Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;1(1):80-7.
doi: 10.1001/jamaoncol.2014.218.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J Maddocks  1 , Amy S Ruppert  1 , Gerard Lozanski  2 , Nyla A Heerema  2 , Weiqiang Zhao  2 , Lynne Abruzzo  2 , Arletta Lozanski  1 , Melanie Davis  1 , Amber Gordon  1 , Lisa L Smith  1 , Rose Mantel  1 , Jeffrey A Jones  1 , Joseph M Flynn  1 , Samantha M Jaglowski  1 , Leslie A Andritsos  1 , Farrukh Awan  1 , Kristie A Blum  1 , Michael R Grever  1 , Amy J Johnson  1 , John C Byrd  1 , Jennifer A Woyach  1
Affiliations

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J Maddocks et al. JAMA Oncol. 2015 Apr.

Abstract

Importance: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up.

Objective: To determine features associated with discontinuation of ibrutinib therapy and outcomes.

Design, setting, and participants: A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014.

Main outcomes and measures: Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse.

Results: With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-"not reached") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient.

Conclusions and relevance: This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not.

Trial registrations: clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: KJM has received research support and has served as a consultant for Pharmacyclics. KAB has received research funding from Pharmacyclics and Janssen. SMJ has received research funding from Pharmacyclics. JAJ has served as a consultant for Pharmacyclics and Janssen. The remaining authors declare no relevant conflict of interest.

Figures

Figure 1
Figure 1. Cumulative Incidence of Discontinuation of Ibrutinib Therapy
Rate of discontinuation is low overall, with relapse-related discontinuations less frequent than non-relapse. Richter’s transformation tends to occur earlier than progression with typical CLL (A). (B) shows close-up curves to highlight differences in discontinuation patterns between CLL progression, Richter’s transformation, and other events.
Figure 1
Figure 1. Cumulative Incidence of Discontinuation of Ibrutinib Therapy
Rate of discontinuation is low overall, with relapse-related discontinuations less frequent than non-relapse. Richter’s transformation tends to occur earlier than progression with typical CLL (A). (B) shows close-up curves to highlight differences in discontinuation patterns between CLL progression, Richter’s transformation, and other events.
See this image and copyright information in PMC

References

    1. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(10):1749–1755. - PMC - PubMed
    1. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(26):3559–3566. - PubMed
    1. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153–2164. - PubMed
    1. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–3397. - PMC - PubMed
    1. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. - PMC - PubMed

Publication types

MeSH terms

Associated data